Literature DB >> 12004801

Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000.

Trisha Suppes1, Ellen B Dennehy, Alan C Swann, Charles L Bowden, Joseph R Calabrese, Robert M A Hirschfeld, Paul E Keck, Gary S Sachs, M Lynn Crismon, Marcia G Toprac, Steven P Shon.   

Abstract

BACKGROUND: The process and outcome of a consensus conference to develop revised algorithms for treatment of bipolar disorder to be implemented in the public mental health system of Texas are described. These medication algorithms for bipolar disorder are an update of those developed for the Texas Medication Algorithm Project, a research study that tested the clinical and economic impact of treatment guidelines for major psychiatric illnesses treated in the Texas public mental health system (Texas Department of Mental Health and Mental Retardation [TDMHMR]).
METHOD: Academic clinicians and researchers, practicing clinicians in the TDMHMR system, administrators, advocates, and consumers participated in a consensus conference in August 2000. Participants attended presentations reviewing new evidence in the pharmacologic treatment of bipolar disorder and discussed the needs of consumers in the TDMHMR system. Principles were enumerated, including balancing of evidence for efficacy, tolerability, and safety in medication choices. A set of 7 distinct algorithms was drafted. In the following months, a subcommittee condensed this product into 2 primary algorithms.
RESULTS: The panel agreed to 2 primary algorithms: treatment of mania/hypomania, including 3 pathways for treatment of euphoric symptoms, mixed or dysphoric symptoms, and psychotic symptoms; and treatment of depressive symptoms. General principles to guide algorithm implementation were discussed and drafted.
CONCLUSION: The revised algorithms are currently being disseminated and implemented within the Texas public mental health system. The goals of the Texas initiative include increasing the consistency of appropriate treatment of bipolar disorder, encouraging systematic and optimal use of available pharmacotherapies, and improving the outcomes of patients with bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12004801     DOI: 10.4088/jcp.v63n0404

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  Olanzapine for the Treatment of Bipolar Disorder.

Authors:  Saeeduddin Ahmed; Elisabeth K. Degenhardt; Hillary C. McGuire
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-06

Review 2.  Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials.

Authors:  Dennis A Revicki; Louis S Matza; Emuella Flood; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 4.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 5.  [Treatment options for bipolar mania].

Authors:  T Attarbaschi; S Kasper
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

6.  Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic.

Authors:  Nick C Patel; M Lynn Crismon; Michael Pondrom
Journal:  J Behav Health Serv Res       Date:  2005 Oct-Dec       Impact factor: 1.505

7.  Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD.

Authors:  Robert C Young; Herbert C Schulberg; Ariel G Gildengers; Martha Sajatovic; Benoit H Mulsant; Laszlo Gyulai; John Beyer; Lauren Marangell; Mark Kunik; Thomas Ten Have; Martha L Bruce; Ruben Gur; Patricia Marino; Jovier D Evans; Charles F Reynolds; George S Alexopoulos
Journal:  Bipolar Disord       Date:  2010-02       Impact factor: 6.744

Review 8.  Gut microbiota and bipolar disorder: a review of mechanisms and potential targets for adjunctive therapy.

Authors:  Shakuntla Gondalia; Lisa Parkinson; Con Stough; Andrew Scholey
Journal:  Psychopharmacology (Berl)       Date:  2019-04-30       Impact factor: 4.530

Review 9.  Quetiapine: a review of its use in the treatment of bipolar depression.

Authors:  Gillian M Keating; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.